Niraparib, marketed globally under the brand name Zejula, is a potent poly (ADP-ribose) polymerase (PARP) inhibitor primarily indicated for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Originally developed by Tesaro and now commercialized by GlaxoSmithKline (GSK), Niraparib has become one of the leading PARP inhibitors in the global oncology market. With the Niraparib industry revenue expected to reach approximately $1.4 billion in 2025 and projected to grow at a 7.1% CAGR through 2034, understanding the global buyer landscape is essential for pharmaceutical companies, API manufacturers, and distributors seeking to enter or expand in this market. This comprehensive guide provides a detailed…